Daniel Menold News Today

Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopharmaceutical company’s stock, valued at approximately $17,629,000. Assenagon Asset Management […]

Monashee Investment Management LLC acquired a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Several other hedge funds and other […]

Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Monashee Investment […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) has received an average rating of “Buy” from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 9.41% from the company’s previous close. Other […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target increased by Jonestrading from $13.00 to $15.00 in a research report report published on Tuesday, Benzinga reports. Jonestrading currently has a buy rating on the biopharmaceutical company’s stock. CBAY has been the subject of several other research reports. Guggenheim began coverage on shares of CymaBay […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target raised by BTIG Research from $18.00 to $22.00 in a research report sent to investors on Friday, MarketBeat reports. BTIG Research currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on CBAY. Guggenheim initiated coverage […]

HC Wainwright reiterated their buy rating on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report report published on Thursday, Benzinga reports. The firm currently has a $19.00 target price on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of CymaBay Therapeutics from […]

Stock analysts at Guggenheim assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $20.00 price target on the biopharmaceutical company’s stock. Guggenheim’s price objective would suggest a potential upside of […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) had its price objective raised by analysts at BTIG Research from $18.00 to $22.00 in a report released on Friday, Marketbeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price would suggest a potential upside of 63.33% from the stock’s […]